Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection

In a phase 2 trial, bepirovirsen, an antisense oligonucleotide that targets all hepatitis B virus mRNAs, resulted in sustained loss of hepatitis B surface antigen and HBV DNA in 9 to 10% of participants with chronic HBV infection.

Uložené v:

Podrobná bibliografia
Vydané v:	The New England journal of medicine Ročník 387; číslo 21; s. 1957 - 1968
Hlavní autori:	Yuen, Man-Fung, Lim, Seng-Gee, Plesniak, Robert, Tsuji, Keiji, Janssen, Harry L.A., Pojoga, Cristina, Gadano, Adrian, Popescu, Corneliu P., Stepanova, Tatyana, Asselah, Tarik, Diaconescu, Gheorghe, Yim, Hyung Joon, Heo, Jeong, Janczewska, Ewa, Wong, Alexander, Idriz, Nevin, Imamura, Michio, Rizzardini, Giuliano, Takaguchi, Koichi, Andreone, Pietro, Arbune, Manuela, Hou, Jinlin, Park, Sung Jae, Vata, Andrei, Cremer, Jennifer, Elston, Robert, Lukić, Tamara, Quinn, Geoff, Maynard, Lauren, Kendrick, Stuart, Plein, Helene, Campbell, Fiona, Paff, Melanie, Theodore, Dickens
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Massachusetts Medical Society 24.11.2022
Predmet:	Alanine transaminase Antigens Antisense oligonucleotides Antiviral Agents - adverse effects Antiviral Agents - therapeutic use Antiviral drugs Chronic infection DNA, Viral - blood Fever Gastroenterology Gastroenterology General Genetics Hepatitis Hepatitis B Hepatitis B e Antigens - blood Hepatitis B surface antigen Hepatitis B Surface Antigens - blood Hepatitis B virus - genetics Hepatitis B, Chronic - drug therapy Hepatitis B, Chronic - virology Humans Hypothesis testing Infections Infectious Disease Injections, Subcutaneous International organizations Laboratories Liver cancer Liver Disease Liver diseases Nucleoside analogs Nucleotide analogs Oligonucleotides, Antisense - administration & dosage Oligonucleotides, Antisense - adverse effects Oligonucleotides, Antisense - therapeutic use Placebos Response rates RNA Therapeutics RNA, Messenger - drug effects RNA, Viral - drug effects Treatment Outcome Viral Infections
ISSN:	0028-4793, 1533-4406, 1533-4406
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!